Please assess the completion status of the following clinical trial:

Trial Title: TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic (\> 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection~* Treatment-naive volunteer, meaning never received (Peg)IFN, RBV or any other approved or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR volunteer is a documented prior non-responder or relapser subject to previous treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at least 6 months before screening~* volunteer has never received a HCV polymerase inhibitor and HCV protease inhibitor treatment was stopped since at least one year (Panels 1, 2 or 3)~* Volunteer with HCV plasma RNA levels of \> 100,000 IU/mL at screening~* Body Mass Index of 18.0 to 35.0 kg/m2~* Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram.~Exclusion Criteria:~* Evidence of liver cirrhosis~* Historical liver biopsy graded as liver cirrhosis or evidence for the presence of oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6 kPa within 2 years prior to screening~* Evidence of decompensated liver disease defined as prior history or current evidence of ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices~* Evidence of renal dysfunction, documented by an estimated creatinine clearance below 70 mL/min~* Evidence of any other cause of significant liver disease in addition to hepatitis C, this may include but is not limited to hepatitis B, drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, or primary biliary cirrhosis~* Volunteer with diagnosed or suspected hepatocellular carcinoma~* Volunteer receiving or having received any treatment for HCV during the 6 months before screening~* Volunteer coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or hepatitis A or B virus infection, or clinically active tuberculosis at study screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 010 (Type: EXPERIMENTAL): TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
- 001 (Type: EXPERIMENTAL): TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
- 002 (Type: PLACEBO_COMPARATOR): placebo. panel 1: 2 participants receive placebo at a q24h regimen.
- 003 (Type: EXPERIMENTAL): TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
- 004 (Type: PLACEBO_COMPARATOR): placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
- 005 (Type: EXPERIMENTAL): TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
- 006 (Type: PLACEBO_COMPARATOR): placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
- 007 (Type: EXPERIMENTAL): TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
- 008 (Type: PLACEBO_COMPARATOR): placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
- 009 (Type: PLACEBO_COMPARATOR): placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).